Streetbeat News

Analyst Ratings

ASND

Goldman Sachs analyst Paul Choi has maintained a Buy rating on Ascendis Pharma and increased the price target from $180 to $200.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:26 pm

ETR

Barclays analyst Nicholas Campanella has upgraded Entergy (NYSE:ETR) from Equal-Weight to Overweight and increased the price target from $115 to $138.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:23 pm

BTG

RBC Capital analyst Wayne Lam has reiterated a Sector Perform rating on B2Gold (AMEX:BTG) and maintained a price target of $3.75.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:21 pm

ORKA

Leerink Partners has initiated coverage on Oruka Therapeutics with an Outperform rating and set a price target of $44.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:18 pm

VSAT

JP Morgan analyst Philip Cusick has downgraded Viasat (NASDAQ:VSAT) from Overweight to Neutral and reduced the price target from $29 to $15.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:11 pm

DELL

DH

INOD

JAKK

LSPD

Top Wall Street analysts initiated coverage on several companies, including Dell Technologies, Lightspeed Commerce, JAKKS Pacific, Definitive Healthcare, and Innodata. Dell received an Outperform rating with a $135 price target, while Lightspeed, JAKKS Pacific, and Definitive Healthcare received Buy ratings. Innodata also received a Buy rating but saw a share price decline.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 1:10 pm

LRCX

Morgan Stanley has maintained its Equal-Weight rating on Lam Research but lowered the price target from $929 to $774, indicating a more cautious outlook.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:06 pm

AMAT

Morgan Stanley analyst Joseph Moore has maintained an Equal-Weight rating on Applied Materials (NASDAQ:AMAT) but has lowered the price target from $224 to $185.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:02 pm